The UK and US have forged a key trade agreement that will guarantee zero import taxes on UK drug exports being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This move secures that tariffs on these vital exports will be held at zero for a timeframe of the next three years.
This deal follows previous statements to hike import taxes on branded pharmaceutical products, with potential rates discussed reaching double the cost.
"This deal with the UK strengthens the international landscape for new treatments and introduces much-needed fairness to transatlantic pharmaceutical trade," a release declared.
Economic Importance
Medicines represent one of the UK's largest export categories to the United States, which is by far the primary buyer for large UK drugmakers.
Export figures indicate that in the one-year period prior to September, the UK shipped drugs worth over eleven billion pounds to the US. This value made up a significant portion of total UK exports in that period.
"This guarantee safeguards employment, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The agreement entails several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to increase total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates topped 20%.
Industry Background
The deal comes amid a protracted row between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
This friction were exacerbated by assertions that US customers were charged significantly more for the same drugs than consumers in the other developed nations.
In recent months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial investments have been announced toward American operations.
The Science Minister publicly accepted that the NHS must spend more on medicines, noting that its spending on drugs had decreased as a proportion of its resources over the previous ten-year period.
